Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Dostarlimab and niraparib in primary advanced ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 11, 2025
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.
Journal: Clinical and translational medicine
Published: April 04, 2025
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 28, 2025
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
Journal: Gynecologic oncology
Published: November 11, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 30, 2019
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Journal: Gynecologic oncology
Published: April 10, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Journal: Gynecologic oncology
Published: September 10, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
Journal: British journal of cancer
Published: February 14, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026